Login / Signup

Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study.

Amy L McKenzieShaminie J Athinarayanan
Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2024)
These results demonstrate the potential for an alternate therapy, such as CRNT supported via telemedicine, to enable maintenance of weight loss and glycemia below therapeutic targets following discontinuation of GLP-1 therapy.
Keyphrases
  • type diabetes
  • weight loss
  • bariatric surgery
  • cardiovascular disease
  • stem cells
  • glycemic control
  • risk assessment
  • adipose tissue
  • metabolic syndrome
  • cell therapy
  • bone marrow
  • human health
  • replacement therapy